Alzprotect develops drug candidates for the treatment of neurodegenerative diseases.
Alzprotect is a biopharmaceutical company that develops drug candidates, from their discovery to clinical trials, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and tauopathies such as Progressive Supranuclear Palsy (PSP).
Alzprotect has developed specific global-level expertise in tauopathies, where neuronal degeneration is a consequence of an abnormal accumulation of hyperphosphorylated Tau proteins combined to neuroinflammation: Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease (AD).
Their expertise led to the discovery of several molecules with novel mechanisms of action, such as AZP2006 that shows potent and promising effects to control neurodegeneration.
AlzProtect was founded in 2007 by André Delacourte, PhD, one of the pioneers in the molecular characterization of neurodegenerative diseases - tauopathies, amyloidopathies and synucleinopathies - and Patricia Melnyk, PhD, an expert in medicinal chemistry.